Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.
Journal: Cancer Cell
Published:
Abstract
BCR-ABL1 compound mutations can lead to resistance to ABL1 inhibitors in chronic myeloid leukemia (CML), which could be targeted by combining the ATP-site inhibitor ponatinib and the allosteric inhibitor asciminib. Here, we report the clinical validation of this approach in a CML patient, providing a basis for combination therapy to overcome such resistance.
Authors
Christopher Eide, Diana Brewer, Tao Xie, Anna Schultz, Samantha Savage, Serena Muratcioglu, Noah Merz, Richard Press, Thomas O'hare, Thomas Jacob, Tania Vu, Cristina Tognon, Tara Macey, John Kuriyan, Charalampos Kalodimos, Brian Druker
Relevant Conditions